Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 2023 Mar 14; 7(5):718-733.
View in:
PubMed
Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 2023 02 28; 7(4):482-490.
View in:
PubMed
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma. Blood. 2023 Feb 09; 141(6):620-633.
View in:
PubMed
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023 Jan 26; 141(4):391-405.
View in:
PubMed
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers (Basel). 2023 Jan 15; 15(2).
View in:
PubMed
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023 01 11.
View in:
PubMed
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023 01 10; 7(1):9-19.
View in:
PubMed
High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. Blood. 2023 Jan 05.
View in:
PubMed
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors. Blood Cancer J. 2022 12 20; 12(12):171.
View in:
PubMed
Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nat Commun. 2022 Dec 13; 13(1):7725.
View in:
PubMed
Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Pharmacoepidemiol Drug Saf. 2022 Dec 02.
View in:
PubMed
RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors. Cancers (Basel). 2022 Nov 20; 14(22).
View in:
PubMed
Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study. Proc Natl Acad Sci U S A. 2022 11 16; 119(46):e2213783119.
View in:
PubMed
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations. J Clin Oncol. 2022 Nov 07; JCO2101987.
View in:
PubMed
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022 09 13; 6(17):4967-4974.
View in:
PubMed
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia. Exp Hematol Oncol. 2022 Sep 12; 11(1):54.
View in:
PubMed
Location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of high-risk NDMM patients. Blood. 2022 Aug 19.
View in:
PubMed
Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders. Blood. 2022 08 18; 140(7):782-785.
View in:
PubMed
?-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022 08 16; 12(8):118.
View in:
PubMed
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica. 2022 08 01; 107(8):1891-1901.
View in:
PubMed
Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. Leuk Res. 2022 09; 120:106921.
View in:
PubMed
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 06 14; 6(11):3332-3338.
View in:
PubMed
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147.
View in:
PubMed
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 Feb 20; 41(6):1265-1274.
View in:
PubMed
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. Haematologica. 2022 06 01; 107(6):1410-1426.
View in:
PubMed
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. J Clin Oncol. 2022 09 20; 40(27):3132-3150.
View in:
PubMed
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022 02 22; 6(4):1309-1318.
View in:
PubMed
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022 05 15; 128(10):1996-2004.
View in:
PubMed
Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat Commun. 2022 02 10; 13(1):807.
View in:
PubMed
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 02 10; 139(6):835-844.
View in:
PubMed
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; 9(2):e143-e161.
View in:
PubMed
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. JAMA Oncol. 2022 02 01; 8(2):281-286.
View in:
PubMed
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH. Blood Adv. 2022 01 25; 6(2):441-451.
View in:
PubMed
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022 04; 36(4):1078-1087.
View in:
PubMed
Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nat Commun. 2022 01 10; 13(1):151.
View in:
PubMed
CD44 v5 domain inhibition represses the polarization of Th2 cells by interfering with the IL-4/IL-4R signaling pathway. Immunol Cell Biol. 2022 01; 100(1):21-32.
View in:
PubMed
CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways. Oncotarget. 2021 Nov 23; 12(24):2323-2337.
View in:
PubMed
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021 11 18; 138(20):1980-1985.
View in:
PubMed
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 11 18; 138(20):1966-1979.
View in:
PubMed
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. Blood Cancer J. 2021 10 08; 11(10):166.
View in:
PubMed
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 01; 27(19):5195-5212.
View in:
PubMed
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin Cancer Res. 2021 10 01; 27(19):5376-5388.
View in:
PubMed
Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021 09 28; 5(18):3511-3514.
View in:
PubMed
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 2021 Nov; 8(11):e794-e807.
View in:
PubMed
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986.
View in:
PubMed
The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability. Genome Med. 2021 08 09; 13(1):127.
View in:
PubMed
Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093.
View in:
PubMed
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2022 01; 36(1):138-154.
View in:
PubMed
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers (Basel). 2021 Jun 25; 13(13).
View in:
PubMed
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 07 24; 398(10297):314-324.
View in:
PubMed
Detection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer J. 2021 06 21; 11(6):117.
View in:
PubMed
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. Am J Hematol. 2021 08 01; 96(8):896-900.
View in:
PubMed
Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. Cancers (Basel). 2021 Jun 18; 13(12).
View in:
PubMed
Idecabtagene Vicleucel in Relapsed Myeloma. Reply. N Engl J Med. 2021 06 17; 384(24):2357-2358.
View in:
PubMed
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 06; 7(23).
View in:
PubMed
Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2021 06 01; 113(6):691-698.
View in:
PubMed
Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. Commun Biol. 2021 05 24; 4(1):617.
View in:
PubMed
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 09; 2(5):468-483.
View in:
PubMed
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discov. 2021 07; 2(4):370-387.
View in:
PubMed
miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 04 08; 137(14):1905-1919.
View in:
PubMed
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
View in:
PubMed
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716.
View in:
PubMed
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.
View in:
PubMed
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e119-e130.
View in:
PubMed
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer J. 2021 01 13; 11(1):13.
View in:
PubMed
Risk factors in multiple myeloma: is it time for a revision? Blood. 2021 01 07; 137(1):16-19.
View in:
PubMed
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. Methods Mol Biol. 2021; 2348:189-204.
View in:
PubMed
In Vitro Silencing of lncRNAs Using LNA GapmeRs. Methods Mol Biol. 2021; 2348:157-166.
View in:
PubMed
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040.
View in:
PubMed
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 12 08; 4(23):5988-5999.
View in:
PubMed
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 12 08; 4(23):6039-6050.
View in:
PubMed
Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723.
View in:
PubMed
Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06.
View in:
PubMed
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020 11 02; 10(11):110.
View in:
PubMed
Don't Compromise Myeloma Care Due to COVID-19 Pandemic! Blood Cancer Discov. 2020 11; 1(3):218-220.
View in:
PubMed
Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020 11; 1(3):258-273.
View in:
PubMed
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 09 08; 4(17):4195-4207.
View in:
PubMed
YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479.
View in:
PubMed
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
View in:
PubMed
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2021 03; 35(3):752-763.
View in:
PubMed
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020 07; 8(2).
View in:
PubMed
Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 Jul; 34(7):1971.
View in:
PubMed
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in:
PubMed
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
View in:
PubMed
Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv. 2020 04 28; 4(8):1643-1646.
View in:
PubMed
Timing the initiation of multiple myeloma. Nat Commun. 2020 04 21; 11(1):1917.
View in:
PubMed
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J Haematol. 2020 Jul; 105(1):35-46.
View in:
PubMed
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 05 15; 80(10):2031-2044.
View in:
PubMed
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol. 2020 03 01; 6(3):425-432.
View in:
PubMed
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 08; 34(8):2150-2162.
View in:
PubMed
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 07; 34(7):1866-1874.
View in:
PubMed
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers (Basel). 2020 Jan 30; 12(2).
View in:
PubMed
RAD51 Inhibitor Reverses Etoposide-Induced Genomic Toxicity and Instability in Esophageal Adenocarcinoma Cells. Arch Clin Toxicol (Middlet). 2020; 2(1):3-9.
View in:
PubMed
Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Adv. 2019 12 10; 3(23):3968-3972.
View in:
PubMed
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019 11 12; 3(21):3360-3374.
View in:
PubMed
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020 02; 34(2):578-588.
View in:
PubMed
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
View in:
PubMed
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 01; 26(1):e7-e15.
View in:
PubMed
Monoclonal Gammopathy May Be of Unpredictable Significance. JAMA Oncol. 2019 Sep 01; 5(9):1302-1303.
View in:
PubMed
Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835.
View in:
PubMed
BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223.
View in:
PubMed
Author Correction: A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019 Jul 25; 10(1):3431.
View in:
PubMed
A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019 07 05; 10(1):2969.
View in:
PubMed
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2020 01; 34(1):167-179.
View in:
PubMed
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. 2019 09; 186(5):e117-e121.
View in:
PubMed
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 05 02; 380(18):1726-1737.
View in:
PubMed
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 07 11; 134(2):160-170.
View in:
PubMed
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019 06 13; 133(24):2615-2618.
View in:
PubMed
Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39.
View in:
PubMed
Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226.
View in:
PubMed
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):372-380.
View in:
PubMed
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):332-344.
View in:
PubMed
Novel Agents in Multiple Myeloma. Cancer J. 2019 Jan/Feb; 25(1):45-53.
View in:
PubMed
Introduction by the Guest Editor: At a Crossroad to Cure: From Molecule to Management Strategies in Multiple Myeloma. Cancer J. 2019 Jan/Feb; 25(1):1.
View in:
PubMed
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6.
View in:
PubMed
Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood. 2018 12 27; 132(26):2778-2780.
View in:
PubMed
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946.
View in:
PubMed
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112.
View in:
PubMed
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2019 03; 25(3):e89-e97.
View in:
PubMed
The roles of homologous recombination and the immune system in the genomic evolution of cancer. J Transl Sci. 2019 Apr; 5(2).
View in:
PubMed
Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance. Blood Cancer J. 2018 09 25; 8(10):92.
View in:
PubMed
A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood Adv. 2018 09 25; 2(18):2400-2411.
View in:
PubMed
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 12 06; 132(23):2456-2464.
View in:
PubMed
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377.
View in:
PubMed
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124.
View in:
PubMed
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438.
View in:
PubMed
Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018 08 22; 9(1):3363.
View in:
PubMed
The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
View in:
PubMed
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018 09 06; 132(10):1050-1063.
View in:
PubMed
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170.
View in:
PubMed
Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018 12; 32(12):2636-2647.
View in:
PubMed
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597.
View in:
PubMed
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018 12; 32(12):2604-2616.
View in:
PubMed
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
View in:
PubMed
Widespread intronic polyadenylation diversifies immune cell transcriptomes. Nat Commun. 2018 04 30; 9(1):1716.
View in:
PubMed
Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight. 2018 04 19; 3(8).
View in:
PubMed
Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
View in:
PubMed
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
View in:
PubMed
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):422-430.
View in:
PubMed
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947.
View in:
PubMed
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018 09; 32(9):1948-1957.
View in:
PubMed
Castleman Disease. Hematol Oncol Clin North Am. 2018 02; 32(1):xiii-xiv.
View in:
PubMed
Diagnosis of Castleman Disease. Hematol Oncol Clin North Am. 2018 02; 32(1):53-64.
View in:
PubMed
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biol Blood Marrow Transplant. 2018 04; 24(4):641-648.
View in:
PubMed
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2017 Dec 06.
View in:
PubMed
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018 04; 32(4):1044-1048.
View in:
PubMed
Expressed fusion gene landscape and its impact in multiple myeloma. Nat Commun. 2017 12 01; 8(1):1893.
View in:
PubMed
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia. 2018 04; 32(4):1003-1015.
View in:
PubMed
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018 04; 32(4):996-1002.
View in:
PubMed
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Nat Commun. 2017 11 20; 8(1):1613.
View in:
PubMed
Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia. 2018 03; 32(3):752-764.
View in:
PubMed
14-3-3? binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia. 2018 03; 32(3):744-751.
View in:
PubMed
Logic programming reveals alteration of key transcription factors in multiple myeloma. Sci Rep. 2017 08 23; 7(1):9257.
View in:
PubMed
Myeloma Minimal Residual Disease and Surrogacy-Reply. JAMA Oncol. 2017 08 01; 3(8):1136-1137.
View in:
PubMed
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 01; 35(25):2911-2918.
View in:
PubMed
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6.
View in:
PubMed
Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2018 01; 32(1):111-119.
View in:
PubMed
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017 10 05; 36(40):5631-5638.
View in:
PubMed
Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. Cancer. 2017 Oct 01; 123(19):3701-3708.
View in:
PubMed
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237.
View in:
PubMed
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res. 2017 Aug 01; 23(15):3980-3993.
View in:
PubMed
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 04 06; 376(14):1311-1320.
View in:
PubMed
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224.
View in:
PubMed
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289.
View in:
PubMed
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. 2017 Aug 01; 23(15):4290-4300.
View in:
PubMed
Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells. J Gastroenterol Hepatol Res. 2017; 6(1):2286-2295.
View in:
PubMed
Genomics of Multiple Myeloma. J Clin Oncol. 2017 Mar 20; 35(9):963-967.
View in:
PubMed
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
View in:
PubMed
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319.
View in:
PubMed
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017 Jan 01; 3(1):28-35.
View in:
PubMed
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.
View in:
PubMed
Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis. Oncoimmunology. 2017; 6(1):e1261776.
View in:
PubMed
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341.
View in:
PubMed
Gene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res. 2016 Nov 15; 22(22):5434-5442.
View in:
PubMed
A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016 09 02; 6(9):e467.
View in:
PubMed
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618.
View in:
PubMed
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346.
View in:
PubMed
DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. Blood. 2016 09 01; 128(9):1214-25.
View in:
PubMed
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016 09 22; 128(12):1590-603.
View in:
PubMed
Review of siltuximab in the treatment of multicentric Castleman's disease. Ther Adv Hematol. 2016 Dec; 7(6):360-366.
View in:
PubMed
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109.
View in:
PubMed
Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. Oncoimmunology. 2016 Aug; 5(8):e1189052.
View in:
PubMed
A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood. 2016 07 14; 128(2):249-52.
View in:
PubMed
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther. 2016 06; 15(6):1364-75.
View in:
PubMed
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36.
View in:
PubMed
A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clin Cancer Res. 2016 Sep 01; 22(17):4350-4355.
View in:
PubMed
Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016 Mar 28.
View in:
PubMed
Corrigendum to "Genomic heterogeneity in multiple myeloma" [Curr. Opin. Genet. Dev. 30 (2015) 56-65]. Curr Opin Genet Dev. 2016 04; 37:158.
View in:
PubMed
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res. 2016 06; 31(6):1225-34.
View in:
PubMed
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. Clin Cancer Res. 2016 Aug 15; 22(16):4039-44.
View in:
PubMed
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15; 6:e380.
View in:
PubMed
Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Res. 2016 Jan 15; 76(2):463-71.
View in:
PubMed
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
View in:
PubMed
Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. Am Soc Clin Oncol Educ Book. 2016; 35:e442-8.
View in:
PubMed
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13.
View in:
PubMed
Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016 05; 30(5):1071-8.
View in:
PubMed
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50.
View in:
PubMed
Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int. 2015; 2015:832049.
View in:
PubMed
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016 Mar 15; 22(6):1378-84.
View in:
PubMed
Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847.
View in:
PubMed
Deficiency of IL-17A, but not the prototypical Th17 transcription factor ROR?t, decreases murine spontaneous intestinal tumorigenesis. Cancer Immunol Immunother. 2016 Jan; 65(1):13-24.
View in:
PubMed
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2016 Mar 01; 22(5):1222-33.
View in:
PubMed
Association of Agent Orange With Plasma Cell Disorder: Further Evidence. JAMA Oncol. 2015 Nov; 1(8):1035-6.
View in:
PubMed
Solitary Extramedullary Multiple Myeloma Presenting with Small Bowel Obstruction. J Emerg Med. 2016 Jan; 50(1):e25-7.
View in:
PubMed
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016 Feb; 30(2):399-408.
View in:
PubMed
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia. 2016 Feb; 30(2):379-89.
View in:
PubMed
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015 Oct 15; 75(20):4384-4397.
View in:
PubMed
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res. 2015 Oct 01; 21(19):4294-304.
View in:
PubMed
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
View in:
PubMed
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
View in:
PubMed
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015 Sep 15; 21(18):4055-61.
View in:
PubMed
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015 Nov; 29(11):2173-83.
View in:
PubMed
Genomic heterogeneity in multiple myeloma. Curr Opin Genet Dev. 2015 02; 30:56-65.
View in:
PubMed
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
View in:
PubMed
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J. 2015 May 15; 5:e312.
View in:
PubMed
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2).
View in:
PubMed
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015 May 14; 125(20):3049-58.
View in:
PubMed
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. Patient. 2015 Apr; 8(2):207-16.
View in:
PubMed
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
View in:
PubMed
Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. Br J Radiol. 2015 May; 88(1049):20140670.
View in:
PubMed
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015 Jun; 29(6):1441-4.
View in:
PubMed
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015 Mar 26; 125(13):2095-100.
View in:
PubMed
Genetics of multiple myeloma: another heterogeneity level? Blood. 2015 Mar 19; 125(12):1870-6.
View in:
PubMed
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43.
View in:
PubMed
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914.
View in:
PubMed
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
View in:
PubMed
Anti-tumor activities of selective HSP90a/ß inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia. 2015 Feb; 29(2):510-4.
View in:
PubMed
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife. 2014 Oct 01; 3.
View in:
PubMed
Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):927-43.
View in:
PubMed
Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015 May; 56(5):1252-60.
View in:
PubMed
Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7.
View in:
PubMed
Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014 Oct 23; 124(17):2675-86.
View in:
PubMed
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014 Nov; 167(3):366-75.
View in:
PubMed
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug; 15(9):966-74.
View in:
PubMed
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11.
View in:
PubMed
CSNK1a1 mediates malignant plasma cell survival. Leukemia. 2015 Feb; 29(2):474-82.
View in:
PubMed
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
View in:
PubMed
CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis. PLoS One. 2014; 9(5):e97566.
View in:
PubMed
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia. 2015 Jan; 29(1):218-29.
View in:
PubMed
Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma. J Clin Oncol. 2016 Jan 10; 34(2):e1-5.
View in:
PubMed
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
View in:
PubMed
Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia. 2014 Nov; 28(11):2229-34.
View in:
PubMed
Processed pseudogenes acquired somatically during cancer development. Nat Commun. 2014 Apr 09; 5:3644.
View in:
PubMed
MRI features of extramedullary myeloma. AJR Am J Roentgenol. 2014 Apr; 202(4):803-10.
View in:
PubMed
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014 Apr 24; 123(17):2673-81.
View in:
PubMed
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13.
View in:
PubMed
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15; 123(20):3128-38.
View in:
PubMed
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
View in:
PubMed
Immunotherapy for multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):91-6.
View in:
PubMed
Reply to M. Roschewski et al. J Clin Oncol. 2014 Feb 10; 32(5):478.
View in:
PubMed
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.
View in:
PubMed
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014 Jan 17; 343(6168):301-5.
View in:
PubMed
A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J. 2013 Nov 01; 3:e156.
View in:
PubMed
The shaping and functional consequences of the dosage effect landscape in multiple myeloma. BMC Genomics. 2013 Oct 02; 14:672.
View in:
PubMed
Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target. Transl Res. 2013 Dec; 162(6):364-70.
View in:
PubMed
Individualized therapy in multiple myeloma: are we there? Semin Oncol. 2013 Oct; 40(5):567-76.
View in:
PubMed
Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
View in:
PubMed
Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma. Br J Haematol. 2013 Nov; 163(3):343-51.
View in:
PubMed
IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb; 28(2):269-77.
View in:
PubMed
Signatures of mutational processes in human cancer. Nature. 2013 Aug 22; 500(7463):415-21.
View in:
PubMed
Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. Leukemia. 2014 Apr; 28(4):894-903.
View in:
PubMed
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014 Mar; 28(3):680-9.
View in:
PubMed
Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55.
View in:
PubMed
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec; 27(12):2366-75.
View in:
PubMed
Minimal residual disease in multiple myeloma. J Clin Oncol. 2013 Jul 10; 31(20):2523-6.
View in:
PubMed
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013 Jun 20; 31(18):2347-57.
View in:
PubMed
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
View in:
PubMed
Challenges in multiple myeloma diagnosis and treatment. Leuk Suppl. 2013 May; 2(Suppl 1):S3-9.
View in:
PubMed
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene. 2014 Mar 20; 33(12):1495-505.
View in:
PubMed
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65.
View in:
PubMed
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31.
View in:
PubMed
Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):181-3.
View in:
PubMed
New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013 Jul 01; 19(13):3337-44.
View in:
PubMed
Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles. PLoS One. 2013; 8(3):e58809.
View in:
PubMed
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013 Apr 15; 19(8):2096-106.
View in:
PubMed
canEvolve: a web portal for integrative oncogenomics. PLoS One. 2013; 8(2):e56228.
View in:
PubMed
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013 Apr; 53(2):487-96.
View in:
PubMed
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8.
View in:
PubMed
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
View in:
PubMed
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71.
View in:
PubMed
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
View in:
PubMed
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
View in:
PubMed
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012 Nov 29; 3:e436.
View in:
PubMed
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
View in:
PubMed
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012 Nov 15; 18(22):6260-70.
View in:
PubMed
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58.
View in:
PubMed
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
View in:
PubMed
Targeted disruption of the BCL9/ß-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 2012 Aug 22; 4(148):148ra117.
View in:
PubMed
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013 Feb; 27(2):473-81.
View in:
PubMed
Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
View in:
PubMed
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13; 120(25):5002-13.
View in:
PubMed
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012 Sep 01; 18(17):4850-60.
View in:
PubMed
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87.
View in:
PubMed
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol. 2012 Jun; 157(6):687-701.
View in:
PubMed
Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81.
View in:
PubMed
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
View in:
PubMed
Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. Cancer Genomics Proteomics. 2012 Mar-Apr; 9(2):55-66.
View in:
PubMed
Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
View in:
PubMed
Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
View in:
PubMed
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
View in:
PubMed
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
View in:
PubMed
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 01; 119(9):2074-82.
View in:
PubMed
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr; 26(4):595-608.
View in:
PubMed
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
View in:
PubMed
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
View in:
PubMed
Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
View in:
PubMed
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 Oct 13; 365(15):1384-95.
View in:
PubMed
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61.
View in:
PubMed
Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011 Oct 15; 17(20):6500-9.
View in:
PubMed
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
View in:
PubMed
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leuk Lymphoma. 2011 Sep; 52(9):1777-86.
View in:
PubMed
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia. 2011 Oct; 25(10):1610-9.
View in:
PubMed
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
View in:
PubMed
Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011 Jul 21; 118(3):675-8.
View in:
PubMed
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
View in:
PubMed
Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. J Clin Oncol. 2011 May 20; 29(15_suppl):8074.
View in:
PubMed
Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11(3):298-302.
View in:
PubMed
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15; 17(10):3259-71.
View in:
PubMed
Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene. 2011 Aug 18; 30(33):3585-98.
View in:
PubMed
Genomics in multiple myeloma. Clin Cancer Res. 2011 Mar 15; 17(6):1234-42.
View in:
PubMed
The dChip survival analysis module for microarray data. BMC Bioinformatics. 2011 Mar 09; 12:72.
View in:
PubMed
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
View in:
PubMed
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 05; 117(18):4696-700.
View in:
PubMed
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5.
View in:
PubMed
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 05; 117(18):4701-5.
View in:
PubMed
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):152-6.
View in:
PubMed
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia. 2011 Apr; 25(4):707-11.
View in:
PubMed
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
View in:
PubMed
Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol. 2010 Dec 01; 3(6):389-99.
View in:
PubMed
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia. 2011 Jan; 25(1):161-8.
View in:
PubMed
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
View in:
PubMed
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010 Oct 20.
View in:
PubMed
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
View in:
PubMed
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
View in:
PubMed
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8.
View in:
PubMed
The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
View in:
PubMed
Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S7-13.
View in:
PubMed
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
View in:
PubMed
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
View in:
PubMed
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
View in:
PubMed
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010 Apr; 9(4):963-75.
View in:
PubMed
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
View in:
PubMed
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5.
View in:
PubMed
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49.
View in:
PubMed
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
View in:
PubMed
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9.
View in:
PubMed
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010 May; 95(5):845-8.
View in:
PubMed
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
View in:
PubMed
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22; 29(16):2325-36.
View in:
PubMed
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34.
View in:
PubMed
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.
View in:
PubMed
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 01; 15(23):7144-52.
View in:
PubMed
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
View in:
PubMed
Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
View in:
PubMed
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
View in:
PubMed
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.
View in:
PubMed
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
View in:
PubMed
Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
View in:
PubMed
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39.
View in:
PubMed
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009 Sep 20; 27(27):4585-90.
View in:
PubMed
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84.
View in:
PubMed
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
View in:
PubMed
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35.
View in:
PubMed
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Oct; 23(10):1904-12.
View in:
PubMed
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
View in:
PubMed
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
View in:
PubMed
Use of alternate splicing to identify subgroups in uniformly treated newly-diagnosed myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):8602.
View in:
PubMed
Clinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):8539.
View in:
PubMed
TNF-a, retinoid acid and STAT4 pathways are differentially regulated by the HDAC inhibitors, SAHA, TSA and Sirtinol in Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):e14582.
View in:
PubMed
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52.
View in:
PubMed
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9.
View in:
PubMed
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
View in:
PubMed
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36.
View in:
PubMed
Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar; 67(3):593-601.
View in:
PubMed
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30; 113(18):4309-18.
View in:
PubMed
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
View in:
PubMed
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009 May; 23(5):961-70.
View in:
PubMed
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60.
View in:
PubMed
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 2009 Mar 05; 113(10):2290-7.
View in:
PubMed
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21.
View in:
PubMed
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62.
View in:
PubMed
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol. 2008 Nov; 143(4):520-31.
View in:
PubMed
The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
View in:
PubMed
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008 Aug 01; 14(15):4971-80.
View in:
PubMed
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008 Oct; 22(10):1925-32.
View in:
PubMed
Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
View in:
PubMed
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.
View in:
PubMed
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5.
View in:
PubMed
Use of high-density SNP-array analysis to identify novel chromosomal abnormalities that predict survival in multiple myeloma. J Clin Oncol. 2008 May 20; 26(15_suppl):8522.
View in:
PubMed
Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008 May 20; 26(15_suppl):8545.
View in:
PubMed
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 2008 Jul; 22(7):1410-8.
View in:
PubMed
Case records of the Massachusetts General Hospital. Case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy. N Engl J Med. 2008 Apr 24; 358(17):1838-48.
View in:
PubMed
Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol. 2008 Jun; 109(3):394-402.
View in:
PubMed
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
View in:
PubMed
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008 May; 141(5):598-606.
View in:
PubMed
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
View in:
PubMed
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9.
View in:
PubMed
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
View in:
PubMed
Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program. 2008; 297.
View in:
PubMed
Investigative tools for diagnosis and management. Hematology Am Soc Hematol Educ Program. 2008; 298-305.
View in:
PubMed
Immune therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1217-30, x-xi.
View in:
PubMed
Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc. 2007 Dec; 82(12):1457-9.
View in:
PubMed
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii.
View in:
PubMed
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64.
View in:
PubMed
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2.
View in:
PubMed
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63.
View in:
PubMed
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9.
View in:
PubMed
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37.
View in:
PubMed
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia. 2007 Dec; 21(12):2519-26.
View in:
PubMed
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
View in:
PubMed
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91.
View in:
PubMed
Integration of novel agents into treatment of myeloma. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S215-21.
View in:
PubMed
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul; 35(7):1038-46.
View in:
PubMed
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68.
View in:
PubMed
Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15; 178(12):7730-7.
View in:
PubMed
New drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89.
View in:
PubMed
Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5.
View in:
PubMed
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
View in:
PubMed
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007 Apr; 11(4):349-60.
View in:
PubMed
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96.
View in:
PubMed
The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
View in:
PubMed
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007 Mar 15; 109(6):2604-6.
View in:
PubMed
Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1.
View in:
PubMed
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood. 2007 Mar 01; 109(5):2001-7.
View in:
PubMed
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7.
View in:
PubMed
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15; 109(4):1669-77.
View in:
PubMed
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007 Apr 05; 26(16):2374-80.
View in:
PubMed
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94.
View in:
PubMed
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006 Oct; 135(2):158-64.
View in:
PubMed
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol. 2006 Oct; 135(1):52-61.
View in:
PubMed
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64.
View in:
PubMed
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol. 2006 Jul; 134(1):37-44.
View in:
PubMed
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82.
View in:
PubMed
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56.
View in:
PubMed
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10.
View in:
PubMed
Novel model to evaluate changes in gene expression profile of myeloma cells in vivo following interaction with human BM microenvironment. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7613.
View in:
PubMed
Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7504.
View in:
PubMed
Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7606.
View in:
PubMed
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006 Aug; 17(8):1275-82.
View in:
PubMed
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73.
View in:
PubMed
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006 Nov 15; 108(10):3441-9.
View in:
PubMed
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704.
View in:
PubMed
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62.
View in:
PubMed
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
View in:
PubMed
Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100.
View in:
PubMed
Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4.
View in:
PubMed
Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8.
View in:
PubMed
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant. 2005 Aug; 36(4):315-23.
View in:
PubMed
Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer. 2005 Jul 15; 4:24.
View in:
PubMed
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906.
View in:
PubMed
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia. 2005 Jul; 19(7):1253-61.
View in:
PubMed
Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma. J Clin Oncol. 2005 Jun; 23(16_suppl):6581.
View in:
PubMed
CYC202 (seliciclib or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, overcomes drug resistance via down-regulation of Mcl-1 in multiple myeloma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):6532.
View in:
PubMed
Novel and potent telomerase antagonist (GRN163L) inhibits telomerase activity, resulting in telomere shortening and apoptosis of multiple myeloma cells. J Clin Oncol. 2005 Jun; 23(16_suppl):6605.
View in:
PubMed
In vivo activity of Atiprimod on SCID models of multiple myeloma. J Clin Oncol. 2005 Jun; 23(16_suppl):6603.
View in:
PubMed
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005 Jun 01; 11(11):4251-8.
View in:
PubMed
A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood. 2005 Aug 15; 106(4):1341-5.
View in:
PubMed
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9.
View in:
PubMed
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 01; 106(3):1042-7.
View in:
PubMed
A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005 Jul 15; 106(2):713-6.
View in:
PubMed
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12.
View in:
PubMed
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6.
View in:
PubMed
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
View in:
PubMed
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53.
View in:
PubMed
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
View in:
PubMed
Focus on multiple myeloma. Cancer Cell. 2004 Nov; 6(5):439-44.
View in:
PubMed
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 Sep 01; 10(17):5692-701.
View in:
PubMed
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
View in:
PubMed
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 01; 104(12):3688-96.
View in:
PubMed
Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6555.
View in:
PubMed
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004 Jul 01; 64(13):4629-36.
View in:
PubMed
Multicentric plasma cell variant of Castleman's disease with cutaneous involvement. J Cutan Pathol. 2004 Jul; 31(6):448-52.
View in:
PubMed
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66.
View in:
PubMed
Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology. 2004 May; 126(5):1337-46.
View in:
PubMed
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene. 2004 Apr 29; 23(20):3597-602.
View in:
PubMed
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
View in:
PubMed
Recent advances in the management of multiple myeloma. Semin Hematol. 2004 Apr; 41(2 Suppl 4):21-6.
View in:
PubMed
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis. 2004 Mar; 9(2):149-55.
View in:
PubMed
Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004 Feb; 65(2):634-41.
View in:
PubMed
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004 Jan 15; 10(2):770-6.
View in:
PubMed
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5.
View in:
PubMed
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66.
View in:
PubMed
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36.
View in:
PubMed
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93.
View in:
PubMed
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
View in:
PubMed
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96.
View in:
PubMed
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 Oct 01; 63(19):6187-94.
View in:
PubMed
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90.
View in:
PubMed
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300.
View in:
PubMed
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8.
View in:
PubMed
Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806.
View in:
PubMed
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003 Sep; 2(9):825-33.
View in:
PubMed
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11.
View in:
PubMed
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9.
View in:
PubMed
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86.
View in:
PubMed
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
View in:
PubMed
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8.
View in:
PubMed
Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):282-5.
View in:
PubMed
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6.
View in:
PubMed
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6.
View in:
PubMed
Infection--an underappreciated cause of bone pain in multiple myeloma. Br J Haematol. 2003 Mar; 120(6):1047-50.
View in:
PubMed
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56.
View in:
PubMed
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.
View in:
PubMed
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.
View in:
PubMed
Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leuk Res. 2003 Jan; 27(1):73-8.
View in:
PubMed
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801.
View in:
PubMed
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14.
View in:
PubMed
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9.
View in:
PubMed
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
View in:
PubMed
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
View in:
PubMed
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4.
View in:
PubMed
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94.
View in:
PubMed
Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 2002 Sep; 16(9):1835-7.
View in:
PubMed
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000.
View in:
PubMed
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
View in:
PubMed
Telomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents. 2002 Sep; 2(5):567-75.
View in:
PubMed
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
View in:
PubMed
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002 Aug; 1(10):851-60.
View in:
PubMed
Novel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1.
View in:
PubMed
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20.
View in:
PubMed
Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82.
View in:
PubMed
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
View in:
PubMed
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
View in:
PubMed
Adeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation. Cancer Res. 2002 May 15; 62(10):2982-5.
View in:
PubMed
Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002 May; 117(2):297-305.
View in:
PubMed
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002 May; 1(7):539-44.
View in:
PubMed
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47.
View in:
PubMed
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58.
View in:
PubMed
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002 Feb; 42(2):205-9.
View in:
PubMed
Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002 Jan; 116(1):211-7.
View in:
PubMed
Interaction of adeno-associated virus Rep78 with SV40 T antigen: implications in Rep protein expression leading to the inhibition of SV40-mediated cell proliferation. Intervirology. 2002; 45(2):115-8.
View in:
PubMed
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 06; 345(23):1655-9.
View in:
PubMed
Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001 Dec; 28(6):565-9.
View in:
PubMed
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001 Sep; 114(4):822-9.
View in:
PubMed
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001 Sep; 114(3):600-7.
View in:
PubMed
Coordination of a transcriptional switch by HMGI(Y) acetylation. Science. 2001 Aug 10; 293(5532):1133-6.
View in:
PubMed
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001 Jul 15; 98(2):492-4.
View in:
PubMed
Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. Cancer Res. 2001 Jun 01; 61(11):4583-90.
View in:
PubMed
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001 May 01; 97(9):2574-9.
View in:
PubMed
Dual level inhibition of E2F-1 activity by adeno-associated virus Rep78. J Biol Chem. 2001 Jun 29; 276(26):24315-22.
View in:
PubMed
CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. AJNR Am J Neuroradiol. 2001 Apr; 22(4):781-5.
View in:
PubMed
Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma. Bone Marrow Transplant. 2001 Mar; 27(6):663-6.
View in:
PubMed
Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein. Exp Hematol. 2001 Jan; 29(1):85-92.
View in:
PubMed
Expression of AAV Rep proteins in SV40-transformed and untransformed cells: reciprocal interaction with host DNA synthesis. Intervirology. 2001; 44(5):298-305.
View in:
PubMed
Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist. 2001; 6 Suppl 2:17-21.
View in:
PubMed
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001 Jan; 112(1):242-7.
View in:
PubMed
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol. 2001 Jan; 112(1):167-74.
View in:
PubMed
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 2000 Oct 15; 96(8):2828-33.
View in:
PubMed
An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Mol Cell Biol. 2000 Oct; 20(20):7572-82.
View in:
PubMed
The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression. J Neurosci. 2000 Oct 01; 20(19):7317-24.
View in:
PubMed
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000 Jun 15; 95(12):4008-10.
View in:
PubMed
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant. 2000 Mar; 25(5):483-7.
View in:
PubMed
c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells. J Immunol. 2000 Feb 01; 164(3):1169-74.
View in:
PubMed
A phase II trial of high dose epirubicin in patients with advanced breast carcinoma. Cancer. 2000 Jan 15; 88(2):375-80.
View in:
PubMed
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18; 341(21):1565-71.
View in:
PubMed
Kaposi's sarcoma-associated herpesvirus-encoded G protein-coupled receptor activation of c-jun amino-terminal kinase/stress-activated protein kinase and lyn kinase is mediated by related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2. J Biol Chem. 1999 Nov 05; 274(45):31863-7.
View in:
PubMed
Novel approaches in myeloma therapy. Semin Oncol. 1999 Oct; 26(5 Suppl 13):28-34.
View in:
PubMed
Bone marrow stromal cells as a vehicle for gene transfer. Gene Ther. 1999 09; 6(9):1611-6.
View in:
PubMed
Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant. 1999 Sep; 24(5):505-9.
View in:
PubMed
Interaction of adeno-associated virus Rep78 with p53: implications in growth inhibition. Cancer Res. 1999 Aug 01; 59(15):3592-5.
View in:
PubMed
Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy. Bone Marrow Transplant. 1999 Jul; 24(1):13-7.
View in:
PubMed
Recent advances in the treatment of multiple myeloma. Curr Opin Hematol. 1999 Jul; 6(4):216-21.
View in:
PubMed
The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J. 1999 Jun 01; 18(11):3074-89.
View in:
PubMed
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol. 1999 Jun; 105(4):938-41.
View in:
PubMed
High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br J Haematol. 1999 Jun; 105(4):993-6.
View in:
PubMed
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999 Jan 01; 93(1):55-65.
View in:
PubMed
Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999 Jan 01; 93(1):51-4.
View in:
PubMed
Lymphomatoid granulomatosis following autologous stem cell transplantation. Bone Marrow Transplant. 1999 Jan; 23(1):79-81.
View in:
PubMed
The IFN-beta enhancer: a paradigm for understanding activation and repression of inducible gene expression. Cold Spring Harb Symp Quant Biol. 1999; 64:149-59.
View in:
PubMed
Initiation and maintenance of multiple myeloma. Semin Hematol. 1999 Jan; 36(1 Suppl 3):9-13.
View in:
PubMed
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol. 1999; 44(6):461-8.
View in:
PubMed
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 1998 Dec 01; 92(11):4269-78.
View in:
PubMed
Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998 Nov; 103(2):530-2.
View in:
PubMed
Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell. 1998 Oct; 2(4):457-67.
View in:
PubMed
Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol. 1998 Jul; 72(7):6131-7.
View in:
PubMed
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant. 1998 May; 21(9):887-92.
View in:
PubMed
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998 May 01; 91(9):3518-23.
View in:
PubMed
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998 Apr; 16(4):1547-53.
View in:
PubMed
In vitro packaging of an infectious recombinant adeno-associated virus 2. Gene Ther. 1997 Nov; 4(11):1167-72.
View in:
PubMed
Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma. 1997 Oct; 27(3-4):351-6.
View in:
PubMed
Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes. Antiviral Res. 1997 Aug; 35(3):177-85.
View in:
PubMed
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997 Jul; 15(7):2659-66.
View in:
PubMed
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant. 1997 Jul; 20(2):113-6.
View in:
PubMed
Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia. Ann Hematol. 1997 Mar; 74(3):111-5.
View in:
PubMed
Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997 Feb 15; 89(4):1334-40.
View in:
PubMed
Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am. 1997 Feb; 11(1):51-69.
View in:
PubMed
Biology and therapy of multiple myeloma in 1996. Semin Hematol. 1997 Jan; 34(1 Suppl 1):67-72.
View in:
PubMed
Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. J Gen Virol. 1996 Jun; 77 ( Pt 6):1111-22.
View in:
PubMed
Graft-versus-myeloma effect: proof of principle. Blood. 1996 Feb 01; 87(3):1196-8.
View in:
PubMed
Adeno-associated virus 2-mediated gene transfer and functional expression of the human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1995 Nov; 23(12):1261-7.
View in:
PubMed
Effect of tumor irradiation on the uptake of lymphokine-activated killer cells in a murine tumor model. Cancer Res. 1994 Apr 01; 54(7):1657-9.
View in:
PubMed
Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer. Invest New Drugs. 1993 May-Aug; 11(2-3):203-5.
View in:
PubMed
Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. Invest New Drugs. 1993 Feb; 11(1):87-90.
View in:
PubMed
Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol. 1993 Jan; 67(1):562-6.
View in:
PubMed
Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors. Invest New Drugs. 1992 Aug; 10(3):159-63.
View in:
PubMed
Growth factor-dependent initiation of DNA replication in nuclei isolated from an interleukin 3-dependent murine myeloid cell line. J Clin Invest. 1990 Jan; 85(1):300-4.
View in:
PubMed